New and emerging targeted systemic therapies: a new era for atopic dermatitis
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
New and emerging targeted systemic therapies: a new era for atopic dermatitis
Authors
Keywords
-
Journal
JOURNAL OF DERMATOLOGICAL TREATMENT
Volume 29, Issue 4, Pages 364-374
Publisher
Informa UK Limited
Online
2017-08-31
DOI
10.1080/09546634.2017.1373736
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- JTE-852, a novel spleen tyrosine kinase inhibitor, blocks mediator secretion from mast cells with immunoglobulin E crosslinking
- (2017) Toshinobu Kato et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- 313 A pathogenic role for Th22/IL-22 in atopic dermatitis is established by a placebo-controlled trial with an anti IL-22/ILV-094 mAb
- (2017) E. Guttman-Yassky et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- The Molecular Revolution in Cutaneous Biology: Investigating the Skin Microbiome
- (2017) Heidi H. Kong et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- The International TREatment of ATopic Eczema (TREAT) Registry Taskforce: An Initiative to Harmonize Data Collection across National Atopic Eczema Photo- and Systemic Therapy Registries
- (2017) Phyllis I. Spuls et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Lebrikizumab improves patient-reported outcomes (PROs) in a phase 2 study in patients with atopic dermatitis
- (2017) JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- A phase 2b dose-ranging efficacy and safety study of tralokinumab in adult patients with moderate to severe atopic dermatitis (AD)
- (2017) JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Ustekinumab treatment in severe atopic dermatitis: Down-regulation of T-helper 2/22 expression
- (2017) Doris Weiss et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- JAK inhibitors in dermatology: The promise of a new drug class
- (2017) William Damsky et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial
- (2017) Andrew Blauvelt et al. LANCET
- Anti–Interleukin-31 Receptor A Antibody for Atopic Dermatitis
- (2017) Thomas Ruzicka et al. NEW ENGLAND JOURNAL OF MEDICINE
- Total IL-12 Levels are Increased in Paediatric Atopic Dermatitis: Correlations with Age and Disease Severity
- (2017) D. Piancatelli et al. INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY
- Efficacy and safety of ustekinumab treatment in adults with moderate-to-severe atopic dermatitis
- (2016) Saakshi Khattri et al. EXPERIMENTAL DERMATOLOGY
- Omalizumab for atopic dermatitis: case series and a systematic review of the literature
- (2016) Jesper Grønlund Holm et al. INTERNATIONAL JOURNAL OF DERMATOLOGY
- Efficacy and safety of multiple doses of QGE031 (ligelizumab) versus omalizumab and placebo in inhibiting allergen-induced early asthmatic responses
- (2016) Gail M. Gauvreau et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- 224 Successful use of secukinumab in an Asian patient with severe refractory atopic dermatitis
- (2016) S. Noda et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: Results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR])
- (2016) Bruce E. Strober et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial
- (2016) Diamant Thaçi et al. LANCET
- Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
- (2016) Eric L. Simpson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Past, present, and future for biologic intervention in atopic dermatitis
- (2015) M. D. Howell et al. ALLERGY
- Pathogenesis of atopic dermatitis
- (2015) W. Peng et al. CLINICAL AND EXPERIMENTAL ALLERGY
- Current novel approaches in systemic therapy of atopic dermatitis
- (2015) Thomas Werfel et al. Current Opinion in Allergy and Clinical Immunology
- Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate
- (2015) Lauren L. Levy et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Simultaneous inhibition of JAK and SYK kinases ameliorates chronic and destructive arthritis in mice
- (2015) Alba Llop-Guevara et al. ARTHRITIS RESEARCH & THERAPY
- Distribution of IL-31 and its receptor expressing cells in skin of atopic dermatitis
- (2014) Atsuhiko Kato et al. JOURNAL OF DERMATOLOGICAL SCIENCE
- Phase 2a, randomized, double-blind, placebo-controlled, multicenter, parallel-group study of a H4R-antagonist (JNJ-39758979) in Japanese adults with moderate atopic dermatitis
- (2014) Yoko Murata et al. JOURNAL OF DERMATOLOGY
- Guidelines of care for the management of atopic dermatitis
- (2014) Robert Sidbury et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Effects of an Anti-TSLP Antibody on Allergen-Induced Asthmatic Responses
- (2014) Gail M. Gauvreau et al. NEW ENGLAND JOURNAL OF MEDICINE
- New era of biologic therapeutics in atopic dermatitis
- (2013) Emma Guttman-Yassky et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Immunologic Effects of Omalizumab in Children with Severe Refractory Atopic Dermatitis: A Randomized, Placebo-Controlled Clinical Trial
- (2013) Shuba Rajashri Iyengar et al. INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY
- Efficacy and safety of systemic treatments for moderate-to-severe atopic dermatitis: A systematic review
- (2013) Evelien Roekevisch et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- A sensory neuron–expressed IL-31 receptor mediates T helper cell–dependent itch: Involvement of TRPV1 and TRPA1
- (2013) Ferda Cevikbas et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Anti-IgE therapy and severe atopic dermatitis: A pediatric perspective
- (2013) Jonathan Lacombe Barrios et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- A Pilot Study of an Oral Phosphodiesterase Inhibitor (Apremilast) for Atopic Dermatitis in Adults
- (2012) Aman Samrao et al. ARCHIVES OF DERMATOLOGY
- Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study
- (2012) K.A. Papp et al. BRITISH JOURNAL OF DERMATOLOGY
- Anti-immunoglobulin E in the treatment of refractory atopic dermatitis
- (2012) D. H. Kim et al. CLINICAL AND EXPERIMENTAL DERMATOLOGY
- Discovery and Development of Spleen Tyrosine Kinase (SYK) Inhibitors
- (2012) Rajinder Singh et al. JOURNAL OF MEDICINAL CHEMISTRY
- Guidelines for treatment of atopic eczema (atopic dermatitis) Part II
- (2012) J. Ring et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Targeted treatment of pruritus: a look into the future
- (2011) H.L. Tey et al. BRITISH JOURNAL OF DERMATOLOGY
- IgE, Mast Cells, and Eosinophils in Atopic Dermatitis
- (2011) Fu-Tong Liu et al. CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY
- Interrupting IL-6–receptor signaling improves atopic dermatitis but associates with bacterial superinfection
- (2011) Alexander A. Navarini et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- A Multicenter, Double-Blind, Randomized, Placebo Controlled Trial of a Neurokinin-1 Receptor Antagonist for Overactive Bladder
- (2010) Tara L. Frenkl et al. JOURNAL OF UROLOGY
- Role of PPAR-gamma in inflammation. Prospects for therapeutic intervention by food components
- (2010) Harry Martin MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS
- Targeting the Neurokinin Receptor 1 with Aprepitant: A Novel Antipruritic Strategy
- (2010) Sonja Ständer et al. PLoS One
- Thymic stromal lymphopoietin, OX40-ligand, and interleukin-25 in allergic responses
- (2009) Y.-H. Wang et al. CLINICAL AND EXPERIMENTAL ALLERGY
- IL-22–producing “T22” T cells account for upregulated IL-22 in atopic dermatitis despite reduced IL-17–producing TH17 T cells
- (2009) Kristine E. Nograles et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- The histamine H4 receptor is functionally expressed on TH2 cells
- (2009) Ralf Gutzmer et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Efficacy of omalizumab in the treatment of atopic dermatitis: A pilot study
- (2008) Lee E. Sheinkopf et al. ALLERGY AND ASTHMA PROCEEDINGS
- A Retrospective Case Series Review of the Peroxisome Proliferator-Activated Receptor Ligand Rosiglitazone in the Treatment of Atopic Dermatitis
- (2008) Ramona Behshad et al. ARCHIVES OF DERMATOLOGY
- Omalizumab for patients with severe and therapy-refractory atopic eczema?
- (2008) Christian Andres et al. CURRENT ALLERGY AND ASTHMA REPORTS
- Correlation of IL-31 serum levels with severity of atopic dermatitis
- (2008) Ulrike Raap et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Anti-CD20 (rituximab) treatment improves atopic eczema
- (2008) Dagmar Simon et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Possible Pathogenic Role of Th17 Cells for Atopic Dermatitis
- (2008) Chizuko Koga et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Atopic Dermatitis
- (2008) Thomas Bieber NEW ENGLAND JOURNAL OF MEDICINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now